AGIO
Price
$34.31
Change
+$0.73 (+2.17%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
1.99B
55 days until earnings call
ZYME
Price
$12.59
Change
+$0.46 (+3.79%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
878.01M
Interact to see
Advertisement

AGIO vs ZYME

Header iconAGIO vs ZYME Comparison
Open Charts AGIO vs ZYMEBanner chart's image
Agios Pharmaceuticals
Price$34.31
Change+$0.73 (+2.17%)
Volume$8.1K
Capitalization1.99B
Zymeworks
Price$12.59
Change+$0.46 (+3.79%)
Volume$5.36K
Capitalization878.01M
AGIO vs ZYME Comparison Chart
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. ZYME commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Buy and ZYME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (AGIO: $33.58 vs. ZYME: $12.13)
Brand notoriety: AGIO and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 63% vs. ZYME: 45%
Market capitalization -- AGIO: $1.99B vs. ZYME: $878.01M
AGIO [@Biotechnology] is valued at $1.99B. ZYME’s [@Biotechnology] market capitalization is $878.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than ZYME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 6 TA indicator(s) are bullish while ZYME’s TA Score has 6 bullish TA indicator(s).

  • AGIO’s TA Score: 6 bullish, 4 bearish.
  • ZYME’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than AGIO.

Price Growth

AGIO (@Biotechnology) experienced а +5.46% price change this week, while ZYME (@Biotechnology) price change was +6.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

AGIO is expected to report earnings on Jul 31, 2025.

ZYME is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($1.99B) has a higher market cap than ZYME($878M). AGIO YTD gains are higher at: 2.191 vs. ZYME (-17.145). ZYME has higher annual earnings (EBITDA): -110.05M vs. AGIO (-434.71M). AGIO has more cash in the bank: 893M vs. ZYME (265M). ZYME has less debt than AGIO: ZYME (18.5M) vs AGIO (52.9M). ZYME has higher revenues than AGIO: ZYME (93.4M) vs AGIO (37M).
AGIOZYMEAGIO / ZYME
Capitalization1.99B878M226%
EBITDA-434.71M-110.05M395%
Gain YTD2.191-17.145-13%
P/E Ratio2.97N/A-
Revenue37M93.4M40%
Total Cash893M265M337%
Total Debt52.9M18.5M286%
FUNDAMENTALS RATINGS
AGIO vs ZYME: Fundamental Ratings
AGIO
ZYME
OUTLOOK RATING
1..100
2012
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1791
PRICE GROWTH RATING
1..100
6155
P/E GROWTH RATING
1..100
8066
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (42) in the Biotechnology industry is in the same range as ZYME (45) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to ZYME’s over the last 12 months.

AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZYME (100) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to ZYME’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for ZYME (91) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew significantly faster than ZYME’s over the last 12 months.

ZYME's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as AGIO (61) in the Biotechnology industry. This means that ZYME’s stock grew similarly to AGIO’s over the last 12 months.

ZYME's P/E Growth Rating (66) in the Pharmaceuticals Major industry is in the same range as AGIO (80) in the Biotechnology industry. This means that ZYME’s stock grew similarly to AGIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 16 days ago
77%
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABEMX14.55N/A
N/A
abrdn Emerging Markets Instl
IYSAX16.41N/A
N/A
Macquarie Smid Cap Core Fund Class A
PCBSX15.13N/A
N/A
BlackRock Tactical Opportunities Service
VRGWX804.08N/A
N/A
Vanguard Russell 1000 Growth Index I
MSSYX8.78N/A
N/A
AMG Frontier Small Cap Growth Z

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with CRNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-1.32%
CRNX - AGIO
48%
Loosely correlated
+0.59%
OLMA - AGIO
47%
Loosely correlated
-0.36%
LGND - AGIO
46%
Loosely correlated
+0.27%
AXON - AGIO
45%
Loosely correlated
+1.08%
ZYME - AGIO
44%
Loosely correlated
-0.57%
More